gastroesophageal junction adenocarcinoma

Showing NaN - NaN of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Worldwide (tucatinib,

Active, not recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Birmingham, Alabama
  • +47 more
Oct 27, 2022

Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8,

Recruiting
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • +27 more
  • Anchorage, Alaska
  • +469 more
Aug 24, 2022

Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Ramucirumab, Capecitabine,

Completed
  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Fayetteville, Arkansas
  • +134 more
Jul 29, 2021

Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer Trial in Boston, Newton (FOLFOX/ nal-IRI, Paclitaxel,

Not yet recruiting
  • Gastroesophageal Junction Adenocarcinoma
  • Esophagogastric Cancer
  • FOLFOX/ nal-IRI
  • +3 more
  • Boston, Massachusetts
  • +2 more
Nov 30, 2020

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Worldwide (Ramucirumab, Paclitaxel)

Completed
  • Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
  • Duarte, California
  • +51 more
Jun 10, 2020

NSCLC, Carcinoma, Renal Cell, Breast Tumors Trial in United States (SGN-2FF, pembrolizumab)

Terminated
  • Carcinoma, Non-Small-Cell Lung
  • +7 more
  • Birmingham, Alabama
  • +10 more
Jul 17, 2019